July 02, 2025

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity risk associated with lean bo...

The ASCO Post

July 01, 2025

Dana-Farber Research News 07.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.

Dana-Farber

June 30, 2025

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

The FDA approved the combination of a PD-1 inhibitor and a CTLA-4 inhibitor for patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer ...

The ASCO Post

June 30, 2025

Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer

Researchers may have identified a bacterial toxin as a potential factor contributing to the concerning rise in early-onset colorectal cancer.

The ASCO Post

June 30, 2025

ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer

Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experience a 50% red...

The ASCO Post

June 30, 2025

AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer

Interim results from the VICTORI study, which were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, showed that an ultrasensitive circulating tumor DNA (ctDNA)-bas...

The ASCO Post

June 30, 2025

DOJ Finds Federal Bureau of Prisons’ Colorectal Cancer Screening Practices Lacking

An evaluation by the Department of Justice (DOJ) Office of the Inspector General of the Federal Bureau of Prisons’ colorectal cancer screening practices for inmates and their clinical follow-up for po...

The ASCO Post

June 30, 2025

Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer

Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete...

The ASCO Post

June 30, 2025

Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer

In a groundbreaking study presented at the 2025 ASCO Gastrointestinal Cancers Symposium, Dr. Anna Martling highlights the substantial reduction in colorectal cancer recurrence risk with adjuvant daily aspirin in patients with PI3K pathway alterations.

The ASCO Post